Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab Versus Methotrexate in Moderate to Severe Psoriasis
2005-000085-39Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in psoriasis comparing Infliximab (Remicade) arm with Methotrexate arm (2 arms). Primary endpoint: PASI75 response at Week 16. Started Jun 2005; status: completed.
02
Drugs
infliximabmethotrexate
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2005-000085-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000085-39.